Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839605 | 0.84 | IDH2 (0.34) | IDH1 | |
| SCHEMBL955898 | 0.72 | PGK1 (0.38) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL37428 | 0.72 | GABRA1 (0.47) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL29079806 | 0.72 | GPR119 (0.46) | IDH1 | |
| SCHEMBL5646151 | 0.69 | GABRA1 (0.36) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL31078226 | 0.69 | IDH1 (0.37) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30041313 | 0.69 | GABRA1 (0.36) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL1437359 | 0.69 | IDH1 (0.37) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL29272376 | 0.69 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL906764 | 0.69 | GABRA1 (0.36) | IDH1GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | IDH1 934/4885GABRA1 229/4885GABRG2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.